Page 517 - Multidisipliner Covid 19

COVID-19 ve Hematoloji

12.Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D,
Wang S, Fan J, Wang W, Deng L, Shi H, Li H, Hu Z, Zhang F, Gao J, Liu
H, Li X, Zhao Y, Yin K, He X, Gao Z, Wang Y, Yang B, Jin R, Stambler
I, Lim LW, Su H, Moskalev A, Cano A, Chakrabarti S, Min KJ, Ellison-
Hughes G, Caruso C, Jin K, Zhao RC. Transplantation of ACE 2- mesen-
chymal Stem cells ımproves the outcome of patients COVID-19 pneu-
monia. Aging and Disease 2020.Vol 11, number 2; 216-228. Doi: 10.14336/
AD.2020.0228.
13.Koehler P, Cornely OA, Böttiger BW, Dusse F, Eichenauer DA, Fuchs
F, Hallek M, Jung N, Klein F, Perssigehl T, Rybniker J, Kochanek M,
Böll B, Shimabukuro- Vornhagen A. COVİD-19 associated pulmonary
aspergillosis. Doi: 10.1111/MYC.13096.
14. Van Arkel ALE. Rijpstra TA, Belderbos HNA, Wijngaarden P, Verweij
PE, Bentvelsen RG. COVID-19 associated pulmonary aspergillosis.
AJRCCM 2020 May 12. Doi; 10.1164/rccm.202004-1038LE.
15. Poston JT, Patel BK, Davis AM. Management of critically III adult with
COVID-19. JAMA 2020. Clinical review_Education.
16. Bikdeli B, Madhavan M, Jimenez D, Chuich T, Dreyfus I, Driggen E.
et al. COVİD-19 and thrombotic or thromboembolic disease: Implications
for prevention, antithrombotic therapy, and follow-up.JACC state-of-
the-Art Review. J Am Coll cardiol. 2020 June 16; 75(23): 2950-2973. Doi:
10.1016/j.jacc.2020.04.031.
17. O’Kelly B, McGettrick P, Angelov D, Fay M, McGinty T, Cotter AG,
Sheehan G, Lambert JS. Outcome of patient with refractory Hodgkin
lymphoma on pembrolizumab, infected with SARS-CoV-2. BJH 2020.
Doi: 10.1111/bjh.16798.
18. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or
chloroquine with or without a macrolide for treatment of COVİD-19:
a multinational registrya nalysis. 2020. Doi: 10.1016/S0140-6736(20)311740.

516